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ABSTRACT
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetically determined disease that progresses 
continuously from conception and throughout life. ARVC/D manifests predominantly in young adulthood. Early identifica-
tion of the concealed cases in childhood is of utmost importance for the prevention of sudden cardiac death later in life. Mag-
netic resonance imaging (MRI) is routinely requested in patients with a confirmed or suspected diagnosis of ARVC/D and 
in family members of the patients with ARVC/D. Although the utility of MRI in the assessment of ARVC/D is well recognized 
in adults, MRI is a low-yield test in children as the anatomical, histological, and functional changes are frequently subtle or 
not present in the early phase of the disease. MRI findings of ARVC/D include morphologic changes such as right ventricu-
lar dilatation, wall thinning, and aneurismal outpouchings, as well as abnormal tissue characteristics such as myocardial fi-
brosis and fatty infiltration, and functional abnormalities such as global ventricular dysfunction and regional wall motion 
abnormalities. Among these findings, regional wall motion abnormalities are the most reliable MRI findings both in chil-
dren and adults, while myocardial fibrosis and fat infiltration are rarely seen in children. Therefore, an MRI protocol should 
be tailored according to the patient’s age and compliance, as well as the presence of other findings, instead of using the pro-
tocol that is used for adults. We propose that MRI in children with ARVC/D should focus on the detection of regional wall 
motion abnormalities and global ventricular function by using a cine imaging sequence and that the sequences for myocardi-
al fat and late gadolinium enhancement of the myocardium are reserved for those who show abnormal findings at cine imaging. 
Importantly, MRI should be performed and interpreted by experienced examiners to reduce the number of false positive and 
false negative readings. (Korean Circ J 2010;40:357-367)
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Introduction
Arrhythmogenic right ventricular cardiomyopathy/dys-
plasia (ARVC/D) has increasingly been recognized as a com-
mon cause of sudden death in young individuals, especially in 
competitive athletes.
1-4) ARVC/D is an inherited myocardial 
disease characterized histopathologically by progressive loss 
and fibrofatty replacement of the myocardium. It is typically 
inherited in an autosomal dominant pattern with variable pe-
netrance. Increasing evidence suggests that genetically deter-
mined disruption of desmosomal integrity is a key factor in 
the development of ARVC/D (Fig. 1).
2)3)5) This view has been 
supported by the identification of mutations in genes encod-
ing desmosomal proteins (desmoplakin, plakoglobin, plako-
philin 2, desmocollin 2, and desmoglein 2) in more than 50% 
of confirmed patients with ARVC/D.
6-9) Desmosomal muta-
tions may affect both right and left ventricles.
10) Impaired des-
mosomal function causes separation of myocytes at their in-
tercalated disks and death of myocytes. Myocardial damage 
from desmosomal dysfunction may be facilitated by mechan-
ical stress such as in endurance exercise.
ARVC/D usually involves the right ventricle preferentially, 
possibly because the thinner right ventricle is more vulnerable 
to mechanical stress than the interventricular septum or the 
left ventricle. It affects predominantly young individuals, par-
ticularly athletes. 358   MRI Assessment of ARVC/D in Children
The natural history of ARVC/D is determined by the elec-
trical instability of the damaged myocardium and the extent 
of myocardial tissue loss (Fig. 1).
10-12) The electrical instability 
can precipitate arrhythmia, causing cardiac arrest and sudden 
death any time during the course of the disease, while the pro-
gressive myocardial loss causes gradual deterioration of the ven-
tricular function and results in heart failure in the later phase 
of the disease. Arrhythmias may occur early in the disease be-
fore development of significant ventricular remodeling or dys-
function, characterizing ARVC/D differently from other forms 
of cardiomyopathies, such as dilated and hypertrophic forms. 
ARVC/D is a challenging diagnosis. This is especially true in 
the pediatric population because ARVC/D is an evolving phe-
notype and the pathological changes are typically subtle in 
children. Imaging modalities used for the evaluation of right 
and left ventricular abnormalities in ARVC/D include con-
ventional angiography, echocardiography, computed tomog-
raphy, and magnetic resonance imaging (MRI). Owing to its 
ability to visualize the right ventricle clearly and to provide the 
most accurate measurements of the ventricular volumes and 
ejection fractions without the use of ionizing radiation, MRI 
is routinely requested in patients with a confirmed or suspect-
ed diagnosis of ARVC/D and in family members of the pa-
tients with ARVC/D in most institutions. 
At the Hospital for Sick Children in Toronto, ARVC/D is 
the second most common indication for cardiovascular MR. 
The purpose of this paper are to summarize the important fea-
tures of ARVC/D in childhood and compare them with those 
seen in later life, and to propose a tailored MRI approach to AR-
VC/D in children. 
Arrhythmogenic Right Ventricular 
Cardiomyopathy/Dysplasia in Children
As a genetically determined disease, ARVC/D progresses 
continuously from conception throughout childhood.
2-4) The 
onset of clinical manifestation is typically during adolescence 
or young adulthood. In a large autopsy series of unexplained 
sudden cardiac death cases, 13% of deaths from ARVC/D oc-
curred under the age of 18 years.
1) Nonetheless, the clinical di-
agnosis of ARVC/D in children is exceedingly challenging as 
pediatric patients infrequently meet the Task Force Criteria 
for Diagnosis of ARVC/D.
4) The so-called ‘concealed phase’ is 
the period of ARVC/D when there is an early predisposition 
to ventricular arrhythmia and sudden cardiac death in the con-
text of well-preserved morphology, histology, and ventricu-
lar function.
13) Most children with ARVC/D would be catego-
rized as being in this phase. 
Early identification of the genetically determined but con-
cealed cases is of utmost importance as the sudden cardiac 
death of the affected patient may be prevented by implement-
ing appropriate and timely medical attention and manage-
ment.
14-16) Corrado et al.
14) showed the dramatic impact of a uni-
versal screening cardiovascular test based on 12-lead elec-
trocardiography (ECG), history, and physical examination in 
young competitive athletes. They showed that the annual in-
cidence of sudden cardiovascular death in athletes decreased 
approximately by 90%, from 3.6/100,000 person-years in the 
pre-screening period to 0.4/100,000 person-years in the late 
screening period, and that most of the reduced death rate was 
due to fewer cases of sudden death from either hypertrophic 
cardiomyopathy or ARVC/D. 
Arrhythmogenic Right Ventricular 
Cardiomyopathy/Dysplasia, 
a Challanging Diagnosis
The diagnosis of ARVC/D can be difficult because of the 
non-specific nature of the clinical findings, broad spectrum of 
phenotypic manifestation, and low accuracy of the individual 
diagnostic tests.
2)3)17) Therefore, the diagnosis of ARVC/D has 
been based on a combination of so-called major and minor 
criteria proposed by the International Task Force in 1994 (Ta-
ble 1).
18) The criteria include those for structural, functional, 
electrocardiographic, arrhythmic, genetic, and histological ab-
normalities. To fulfill the appropriate criteria for ARVC/D, pa-
tients must have two major criteria, one major and two minor 
criteria, or four minor criteria. However, the diagnosis based 
on these 1994 Task Force criteria has been shown to lack sen-
sitivity for identification of early/minor phenotypes, particu-
larly in the setting of familial ARVC/D. A further limitation of 
the 1994 criteria was the lack of quantitative cut-off values for 
dilatation, reduced ejection fraction, and fibrofatty myocardial 
replacement of the right ventricular (RV). They also did not adjust 
for differences in normal values within a pediatric population. 
The reliability of diagnostic tests is also strongly questioned. 
A large prospective multicenter study showed considerable 
discrepancies between the initial and final diagnosis follow-
Born with mutation in genes 
encoding desmosomal proteins
Pathogenesis Mechanism Clinical phases
Concealed phase
Arrhythmic phase
Heart failure phase
Electrical 
uncoupling
of the cells
Progressive loss 
of myocardial
tissue
Disruption of cell-cell adhesions
Detachment of myocytes
Myocardial inflammation
Myocardial fibrosis
Fatty replacement
Fig. 1. Proposed pathogenesis and natural history of arrhythmo-
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Table 1. Original (1994) and Revised (2010) Task Force Criteria for Diagnosis of ARVC/D
1994 Original Task Force Criteria 2010 Revised Task Force Criteria
I.   Global or regional dysfunction and structural alterations
Major
      •   Severe RV dilatation and reduced RVEF 
  with no or only mild LV impairment
      •   Localized RV aneurysms (akinetic or  
 dyskinetic areas of diastolic bulging)
      •   Severe segmental dilatation of the RV
2D echo
   • Regional RV akinesia, dyskinesia or aneurysm
   • and 1 of the following (end diastole):
      -   RVOT at LAX ≥32 mm (≥19 mm/m
2)
      -   RVOT at SAX ≥36 mm (≥21 mm/m
2)
      -   or fractional area change ≤33%
MR
   • Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
   • and 1 of the following:
      -   RVEDVi ≥110 mL/m
2 for male or ≥100 mL/m
2 for female
      -   or RVEF ≤40%
RV angiography
   • Regional RV akinesia, dyskinesia or aneurysm
Minor
      •     Mild global RV dilatation and/or reduced 
 RVEF with normal LV
      •     Mild segmental dilatation of the RV
      •     Regional RV hypokinesia
2D echo
   • Regional RV akinesia or dyskinesia 
   • and 1 of the following (end diastole):
      -   RVOT at LAX ≥29 to <32 mm (≥16 to <19 mm/m
2)
      -   RVOT at SAX ≥32 to <36 mm (≥18 to <21 mm/m
2)
      -   or fractional area change >33% to ≤40%
MR
   • Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
   • and 1 of the following:
      -   RVEDVi ≥100 to <110 mL/m
2 for male or ≥90 to <100 mL/m
2 for female
      -   or RVEF >40% to ≤45%
II. Tissue characterization of wall
Major
      Endomyocardial biopsy
         - Fibrofatty replacement of myocardium 
Endomyocardial biopsy
      -   Residual myocytes <60% by morphometric analysis (or <50% if estimated),  
 with fibrous replacement of the RV free wall myocardium in ≥1 sample,  
 with or without fatty replacement of tissue 
Minor
Endomyocardial biopsy
   -   Residual myocytes 60-75% by morphometric analysis (or 50-65% if  
 estimated), with fibrous replacement of the RV free wall myocardium  
 in ≥1 sample, with or without fatty replacement of tissue 
III. Repolarization abnormalities
Major
-   Inverted T waves in right precordial leads (V1, V2 and V3) or beyond in 
 individuals >14 years of age (in the absence of complete RBBB QRS ≥120 ms)
Minor
      -   Inverted T waves in right precordial leads 
 (V2 and V3) (people age >12 years, 
 in absence of RBBB)
-   Inverted T waves in leads V1 and V2 in individuals >14 years of age (in the
  absence of complete RBBB) or in V4, V5 or V6
-   Inverted T waves in leases V1-4 in individuals >14 years of age in the presence 
 of complete RBBB
IV. Depolarization abnormalities
Major
      -   Epsilon waves or localized QRS  
 prolongation (>110 ms) in right precordial  
 leads (V1 to V3)
-   Epsilon waves (reproducible low-amplitude signals between end of QRS  
 complex to onset of the T wave) in right precordial leads (V1 to V3)360   MRI Assessment of ARVC/D in Children
ing evaluation of the tests by the core laboratories.
17) This study 
also showed the favorable diagnostic performance of echocar-
diogram, right ventricular angiogram, signal-averaged elec-
trocardiography (SAECG) and ECG, and inferior perfor-
mance of MRI and right ventricular biopsy. 
Modifications of the original Task Force criteria have recent-
ly been proposed (Table 2).
19) The revised criteria provide guid-
ance on the role of emerging diagnostic modalities and ad-
vances in the genetics of ARVC/D to improve the diagnostic 
sensitivity with the diagnostic specificity maintained. The 
revised criteria include quantitative criteria that define the ab-
normalities on the basis of comparison with normal data, and 
some of the imaging criteria now adjust for patient size. The 
quantitative data for global or regional dysfunction and struc-
tural alterations are provided by either echocardiography or 
MRI. The modified Task Force criteria are expected to improve 
the diagnosis and management of ARVC/D. 
A definitive diagnosis of ARVC/D is still based on histolog-
ical demonstration of transmural fibrofatty replacement of RV 
myocardium at biopsy, necropsy, or surgery.
19) However, the 
diagnosis based on right ventricular endomyocardial biopsy 
is limited because of the segmental nature of the disease, ear-
lier and more severe involvement of the subepicardial than the 
subendocardial region of the myocardium, and apparent risk 
Table 1. Continued
1994 Original Task Force Criteria 2010 Revised Task Force Criteria
Minor
      -   Late potentials (SAECG) -   Late potentials by SAECG ≥1 of 3 parameters in the absence of a QRS duration 
  of ≥110 ms on the standard ECG
-   Filtered QRS duration (fQRS) ≥114 ms
-   Duration of terminal QRS <40 μV (low-amplitude signal duration) ≥38 ms
-   Root-mean-square voltage of terminal 40 ms ≤20 μV
-   Terminal activation QRS ≥55 ms measured from the nadir of the S wave to the 
 end of the QRS, including R', in V1, V2 or V3 in the absence of complete RBBB
  V. Arrhythmias 
Major
-   Nonsustained or sustained ventricular tachycardia of RV outflow configuration, 
 LBBB morphology with superior axis (negative or indeterminate QRS in lese II, 
 III and aVF and positive in lead aVL)
Minor
      -   LBBB type ventricular tachycardia  
 (sustained or nonsustained)  
 (ECG, Holter, exercise)
      -   Frequent ventricular extrasystoles  
 (>1000 per 24 hours) (Holter)
-   Nonsustained or sustained ventricular tachycardia of RV outflow configuration, 
 LBBB morphology with inferior axis (positive QRS in lese II, III and aVF and   
 negative in lead aVL)
-   >500 ventricular extrasystoles per 24 hours (Holter)
VI. Family history
Major
      -   Familial disease confirmed at necropsy  
 or surgery
-   ARVC/D confirmed in a first-degree relative who meets current Task Force  
 criteria
-   ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative 
-   Identification of a pathogenic mutation* categorized as associated or probably
 associated with ARVC/D in the patient under evaluation
Minor
      -   Family history of premature sudden death  
 (<35 years of age) due to suspected ARVC/D
      -   Familial history (clinical diagnosis based  
 on present criteria)
-   History of ARVC/D in a first-degree relative in whom it is not possible or  
 practical to determine whether the family member meets current Task Force  
 criteria
-   Premature sudden death (<35 years of age) due to suspected ARVC/D in a  
 first-degree relative 
-   ARVC/D confirmed pathologically or by current Task Force criteria in a  
 second-degree relative
Diagnostic terminology for original criteria: This diagnosis is fulfilled by the presence of 2 major, or 1 major plus 2 minor criteria or 4 minor 
criteria from different groups. Diagnostic terminology for revised criteria: definite diagnosis: 2 major or 1 major and 2 minor criteria or 4 
minor from different categories; borderline: 1 major and 1 minor or 3 minor criteria from different  categories; possible: 1 major or 2 minor 
criteria from different categories. aVF: augmented voltage unipolar left foot lead, aVL: augmented voltage unipolar left arm lead, LAX: para-
sternal long-axis view, RV: right ventricle, RVEDVi: right ventricular end-diastolic volume indexed to the body surface area, RVEF: right 
ventricular ejection fraction, RVOT: right ventricular outflow tract, SAX: parasternal short-axis view, SAECG: signal-averaged electrocardi-
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in taking biopsy samples from the right ventricular free wall 
where the histopathologic changes of the disease are typically 
seen. Asimaki et al.
20) recently introduced the immunohisto-
chemical analysis of a conventional endomyocardial-biopsy 
sample as a new diagnostic test for ARVC/D. They showed an 
excellent diagnostic value of reduced plakoglobin levels in 
the biopsy sample, with a sensitivity of 91%, a specificity of 82%, 
a positive predictive value of 83%, and a negative predictive 
value of 90%. Importantly, the plakoglobin level was reduced 
not only in the right ventricle, but also in the left ventricle 
and interventricular septum. This will allow wider use of en-
domyocardial biopsy as tissue sampling does not have to be 
restricted to the histologically abnormal myocardium of the 
thin-walled right ventricle. Thus, immunohistochemical 
analysis may facilitate the early and more definitive diagnosis 
of ARVC/D. However, the utility of this promising test has 
yet to be proven by a prospective study in a larger cohort.
Magnetic Resonance Imaging Protocol 
and Findings of Arrhythmogenic Right 
Ventricular Cardiomyopathy/Dysplasia
With its capability to image the heart without ionizing ra-
diation and high reproducibility, MRI is, at least from a fea-
sibility and safety point of view, best suited for serial assess-
ment of the index cases and screening of asymptomatic family 
members. The aim of MRI is to assess the morphologic chang-
es, abnormal tissue characteristics, and functional abnormal-
ities of ARVC/D (Table 2 and 3).
21-13) The standard MRI pro-
tocol includes the sequences for assessment of myocardial 
thinning, aneurysms, fibrosis, fatty infiltration, and regional 
and global ventricular function (Table 3). When a patient 
Table 2. MRI findings of ARVC/D
21-23)
Category MRI finding Probands (%)
21)22) Family members 
with mutation (%)
23)
Family members 
without mutation (%)
23)
Morphologic 
  changes
Right ventricular dilatation
Right ventricular outflow tract dilatation
Ventricular wall thinning
Aneurysmal outpouchings
   - Accordion sign
Ventricular wall hypertrophy
Trabecular hypertrophy/disarray
22
17
05
24
60
8
0
Abnormal tissue 
  characteristics
Myocardial fibrosis
   - Right ventricle
   - Left ventricle
Fatty replacement of myocardium
   - Right ventricle
   - Left ventricle
67* 
60
15
20
00
28
16
0
0
0
0
Functional 
  abnormalities
Global ventricular dysfunction
   - Right ventricle
   - Left ventricle
Regional dysfunction of the right ventricular wall
   - Basal 
   - Mid ventricular
   - Outflow tract
   - Apical
60
13
80
70
65
46
40
16
00
24
8
0
0
ARVC/D: arrhythmogenic right ventricular cardiomyopathy/dysplasia
Table 3. MRI sequences in assessment of ARVC/D
Sequence Plane Purpose
Fast spin-echo imaging with double inversion recovery Axial
Short-axis
Morphology/Fatty replacement of myocardium
Cine steady-state free precession (SSFP) imaging Axial
Short-axis
RVOT
Morphology/Regional and global ventricular function
Late gadolinium enhancement imaging Axial
Short-axis
RVOT
Myocardial fibrosis/Myocardial wall thickness
ARVC/D: arrhythmogenic right ventricular cardiomyopathy/dysplasia, RVOT: right ventricular outflow tract362   MRI Assessment of ARVC/D in Children
shows frequent extrasystole during the examination, suppres-
sion of ventricular extrasystole with antiarrhythmic medica-
tion is important for optimal imaging. Table 4 summarizes 
the medication used at the Hospital for Sick Children in To-
ronto. If the patient shows evidence of suppression of ectopy 
at higher heart rates, either in a 24-hour Holter recording or 
during an exercise test, our drug of choice is atropine, followed 
by lidocaine and, in rare cases, isoproterenol. These medica-
tions require close observation with continuous monitoring 
of the heart rate, oxygen saturation, and blood pressure. When 
medication is used, a physician must be present during the en-
tire examination and prepared to intervene in case of a cardio-
vascular emergency. 
Morphologic changes 
Dilatation of the right ventricle is a nonspecific but com-
mon finding of ARVC/D (Fig. 2). In a study by Tandri et al.
24) 
the patients who met the 1994 Task Force criteria for diag-
nosis of ARVC/D showed a linear correlation between the du-
ration of symptoms and right ventricular end diastolic vol-
ume index. Disproportionate dilatation of the right ventricular 
outflow tract is often seen but is a subjective finding. Although 
myocardial thinning is considered common pathologically, 
its recognition at MRI is challenging as the right ventricular 
myocardium is normally thin. Therefore, it is important to im-
Table 4. Antiarrhythmic medication for MRI in patients with frequent extrasystoles
Drug Dose Maximum dose Mode of IV injection
Atropine 0.02 mg/kg 1.5 mg Bolus
Lidocaine 0.5 mg/kg 50 mg Infusion over a period of 2 minutes
Isoproterenol 0.01-0.02 μg/kg/min 0.03 μg/kg/min Infusion
This regime is not a recommendation, but merely reflects the practice at the Hospital for Sick Children
Fig. 2. Short axis cine MRI images show right ventricular dilatation and randomly oriented prominent trabeculae in the apical part of the right 
ventricle. The 3-dimensional volume model on the right shows significant discrepancy in right (RV) and left (LV) ventricular volumes.  
Fig. 3. An axial cine image shows thinning and crinkling of the infe-
rior part of the free wall of the RV. Small outpouchings (arrows) give 
rise to an appearance of an accordion. RV: right ventricle, LV: left 
ventricle. 
RV
LV
Fig. 4. A T1-weighted spin-echo image in axial plane shows a high 
signal intensity area in the subepicardial region of the posterior wall 
(arrow) of the left ventricle (LV). High signal intensity (arrow) is also 
seen in the moderator band of the right ventricle (RV). Both are con-
sidered fatty infiltration in the myocardium and the myocardial biop-
sy demonstrated fatty replacement of the myocardium. 
RV
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age the pathological areas in strictly perpendicular planes. 
In adults, myocardial thinning is considered when focal and 
abrupt reduction in wall thickness to <2 mm is seen.
21) Myo-
cardial thinning appears more convincing when it is associat-
ed with aneurismal outpouchings. Small multiple outpouch-
ings may give rise to an appearance of focal crinkling, namely 
an “accordion sign” which becomes more prominent during 
systole (Fig. 3).
23) The “accordion sign” is most commonly seen 
in the right ventricular outflow tract and subtricuspid regions. 
Dalal et al.
23) showed the “accordion sign” in 60% of the muta-
tion carriers of the family members of the desmosomal muta-
tion-carrying probands of ARVC/D and in none of the indivi-
duals without a desomosomal mutation.
24) Therefore, the “ac-
cordion sign” is considered an early sign of ARVC/D in asymp-
tomatic patients, reflecting an early stage of the disease.
23)25) Hy-
pertrophy of the free wall and/or trabeculations of the right ven-
tricle are only occasionally seen (Fig. 2). 
Abnormal tissue characteristics 
The earlier papers on MRI utilization in the diagnosis of 
ARVC/D invariably emphasized the ability of MRI to char-
acterize fatty infiltration of the myocardium.
26-30) Spin-echo 
black-blood imaging sequences visualize the fat with high-
intensity signals in contrast to intermediate signals of normal 
myocardium (Fig. 4). Perhaps the ability of the MRI to visual-
ize fat had led to explosive use of MRI in the assessment of 
ARVC/D. However, identification of myocardial fat was po-
Fig. 5. Idiopathic fatty myocardium. Black blood images obtained 
with the double-inversion recovery technique (upper panels) show 
high-signal intensity fat (arrow) in the lower part of the interventric-
ular septum. Images obtained with the triple-inversion recovery te-
chnique (lower panels) show suppression of the high intensity sig-
nals of the subcutaneous and epicardial fat as well as the myocar-
dial fat. The patient had pulmonary atresia with intact ventricular 
septum and underwent surgical pulmonary valvotomy. The ventric-
ular function was normal. 
Fig. 6. A late gadolinium enhancement image shows a thinned ri-
ght ventricular (RV) wall. The apical part of the thinned free wall of RV 
shows enhancement (arrows). A small area of enhancement (arrow) 
is also seen in the posterior wall of the left ventricle (LV).
LV
RV
RA
LV LV RV RV
Diastole Systole
Fig. 7. Late gadolinium enhancement images obtained in diastole (left panel) and in systole (right panel) in a normal individual. Note that the 
myocardium of the free wall of the RV is better defined in systole than in diastole. RV: right ventricle, LV: left ventricle. 364   MRI Assessment of ARVC/D in Children
orly reproducible among readers.
31-33) As fibrofatty replace-
ment starts from the subepicardial layer of normal myocar-
dium and extends toward the subendocardial layer, the early 
histopathological changes are difficult to discriminate from 
the adjacent epicardial fat. In addition, normal slow flow along 
the endocardial surface may produce high-intensity signals 
that may be difficult to differentiate from the signals from fat. 
Although fat-suppression technique (Fig. 5) can be used for dis-
crimination of the fat from the slow-flow artifact, the detec-
tion of myocardial fat remains difficult and subjective. Further-
more, recognition of fat in the normal ventricular myocardium 
has rendered the diagnostic value of fatty infiltration by MRI 
of limited value, especially in elderly population and obese in-
dividuals who do not have ARVC/D (Fig. 5).
34)35) Fatty infiltra-
tion with right ventricular thickness ≥ 6 mm, but without re-
gional or global functional abnormalities, is considered distinct 
from fatty right ventricle in ARVC/D.
36) Importantly, fat infil-
tration is seldom the only abnormality of ARVC/D.
21) 
Late gadolinium enhancement allows recognition of myo-
cardial fibrosis involving the ventricular septum and the left 
ventricle.
23)37)38) Enhancement of the left ventricle is usually 
easy to identify. However, it is a real practical challenge to 
identify the enhancing myocardium of the right ventricle be-
cause of the thin thickness of the right ventricular free wall 
and the presence of a layer of epicardial fat that also shows 
high-intensity signals (Fig. 6). In addition, the free wall of the 
right ventricle may normally show a higher signal than the 
other parts of the myocardium when a surface coil is used. Fat 
suppression may allow better definition of fibrotic myocar-
dium by eliminating the signal from the epicardial fat. The dif-
ficulty in assessment of the right ventricle appears also due to 
timing of routine late gadolinium imaging to late diastolic 
phase when the ventricular wall is thinnest. This limitation 
could be overcome by obtaining late gadolinium enhance-
ment imaging in end-systolic phase when the myocardium is 
thickened (Fig. 7).
30) Left ventricular late enhancement is ob-
served in the setting of global right ventricular dysfunction 
in the classic form of ARVC/D.
10) The predilection sites for left 
ventricular enhancement are the inferolateral wall and infe-
rior wall-septal junction. Localized late enhancement of the left 
ventricle occurs frequently without concomitant wall motion 
abnormality, ventricular dilatation, or significant systolic dys-
function.
23)
Functional abnormalities
Regional right ventricular dysfunction is present in most of 
the patients with ARVC/D (Fig. 8).
21)38)40) It is the most sensi-
tive and specific finding in ARVC/D. It represents regional 
loss of myocytes and precedes changes in global right ven-
tricular function.
21) Regional dysfunction is seen in a form 
of akinesia or dyskinesia, which is often difficult to perceive. 
The wall motion should be assessed region by region. We find 
placement of a reference cursor on the center of the ventric-
ular cavity during cine display of the images helpful. Akinet-
ic or dyskinetic motion of the affected wall can be perceived 
as absence of motion toward the cursor or apparent outward 
protrusion during systole. Dyssynchronous contraction of 
the ventricular wall has also been described but is subjective and 
appears more difficult to recognize. 
The modified Task Force criteria of 2010 included akinesia, 
dyskinesia, or dyssynchronous contraction of the right ven-
tricle as the major criterion when it is associated with overt 
dilatation or systolic dysfunction of the right ventricle, and as 
the minor criteria when it is associated with borderline dilata-
tion and systolic dysfunction of the right ventricle.
19) ARVC/D 
is also associated with regional left ventricular dysfunction. 
Jain et al.
41) demonstrated decreased regional left ventricular 
contraction by using tagged MRI in patients with a definite or 
Fig. 8. Cine images in 2-chamber view of the right ventricle show right ventricular dilatation, poor systolic function, and dyskinesia of the anterior 
wall of the right ventricular outflow tract (arrow). The right ventricular contour was drawn on the diastolic image as shown in the left panel. The 
contour was copied and overlain on the systolic image as shown in the right panel. Note the minimal downward excursion of the base of the right 
ventricle in systole. The anterior wall of the right ventricular outflow tract shows protrusion in systole beyond the limit of right ventricular contour 
drawn on the diastolic image. 
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probable diagnosis of ARVC/D. 
The right ventricle shows progressive reduction in systolic 
function and dilatation with time (Fig. 8). End stage ARVC/D 
is characterized by right heart failure with a grossly dilated 
right ventricle. On the other hand, overtly reduced ejection fr-
action of the right ventricle is seen only occasionally in early 
stage of the disease. Global left ventricular dysfunction is seen 
only in severe cases, although regional dysfunction is not un-
common.
41)
Summary of magnetic resonance imaging findings
of arrhythmogenic right ventricular cardiomyopathy/
dysplasia
Among the described MRI findings of ARVC/D, regional 
wall motion abnormalities are considered as the most reliable 
finding. Crinkling of the right ventricular wall with small mul-
tiple outpouchings, namely an “accordion sign” appears to be 
a sensitive morphological finding.
23) Quantification of the ven-
tricular volumes provides additional objective data. Late gad-
olinium enhancement appears to play an important role in 
detection of left ventricular involvement. Originally regarded 
as a key MRI finding in ARVC/D, intramyocardial fat is far 
from reliable, particularly when it is an isolated finding.
Tailored Magnetic Resonance Imaging 
Approach to Arrhythmogenic Right 
Ventricular Cardiomyopathy/
Dysplasia in Children
Despite the wide use of MRI as a diagnostic tool in ARVC/D 
in the last two decades, it has received a more guarded recep-
tion than it originally had owing to interobserver variability 
and lack of standard protocols.
17)38) Although MRI appears to 
be a highly sensitive test in patients fulfilling 1994 Task Force 
criteria, the diagnosis of ARVC/D can be made without MRI 
as other imaging modalities are likely to provide the relevant 
information.
38) The most recent report of the North American 
Multidisciplinary Study of ARVC/D showed a disappointing-
ly low diagnostic performance of MRI compared with other 
diagnostic tests, including echocardiography and angiogra-
phy.
17) The diagnostic yield of MRI for ARVC/D is significantly 
lower in the pediatric age group than in adults.
43) In fact, it 
needs to be determined whether MRI is a cost-effective test for 
the diagnosis of ARVC/D in children and whether the MRI 
protocol and criteria used for adults are equally applicable to 
children. 
At the Hospital for Sick Children in Toronto, 100 MRI ex-
aminations were performed for children with a known or 
suspected diagnosis or family history of ARVC/D in 2008 us-
ing the study protocol listed in Table 3. One study failed be-
cause of sustained arrhythmias. Thirty-four individuals showed 
one or more positive findings (Table 5). Right ventricular dil-
atation, reduced right ventricular ejection fraction, and region-
al wall motion abnormalities with thinning of the myocardi-
um or focal aneurysm were the most common findings that 
were seen in 14-20% of the cases. However, no case showed 
myocardial fat or positive results of late gadolinium enhance-
ment. In Fogel et al’s study,
43) only 2 of 81 children referred for 
MRI evaluation of ARVC/D showed evidence of fatty infil-
tration in very small areas of the right ventricle. The results of 
Fogel et al.
43) and our study are in contrast to the results of Avi-
ram et al.
44) that demonstrated MRI signals compatible with 
fat in 70% of 26 patients aged 4-17 years. Considering that de-
tection of intramyocardial fat is hampered by a high interob-
server variability
32) and fatty replacement of the myocardium 
is the latest pathological manifestation of loss of myocardium, 
the high incidence of intramyocardial fat in their pediatric 
population seems questionable. In our routine MRI protocol 
(Table 3), approximately one third of the scan time is used 
for imaging the fat and late gadolinium enhancement. On 
the other hand, positive results for myocardial fat and late 
gadolinium enhancement are almost exclusively seen in as-
sociation with other findings, such as ventricular wall motion 
abnormalities, aneurismal outpouchings, and significant 
ventricular dilatation. Therefore, the likelihood of positive 
results for myocardial fat and fibrosis is almost none if cine 
imaging does not show any abnormality.
As young pediatric patients are less compliant than adults, 
it is important to perform the sequences with a higher chance 
of positive finding in the early part of the examination be-
fore the patient gets tired and noncompliant. In this regard, 
cine imaging of the heart in axial, short-axis, and right ventric-
Table 5. Distribution of abnormal findings in 100 MRI examinations in 2008 at the hospital for sick children 
MRI findings Overall incidence Incidence as a sole finding
Right ventricular dilatation 20 10
Reduced ejection fraction of the right ventricle 17 03
Regional wall motion abnormality/Thinning of the myocardium/Anerurysm 14 04
Right ventricular outflow tract dilatation 02 01
Left ventricular dilatation/Reduced ejection fraction 09 00
Myocardial fat 00 00
Late gadolinium enhancement 00 00366   MRI Assessment of ARVC/D in Children
ular outflow tract planes should be performed first, while the 
fast-spin echo imaging and late gadolinium enhancement im-
aging are reserved for those who show abnormalities at cine 
imaging. When the patient has had or shows arrhythmias, an 
intravenous route is secured for antiarrhythmic medication to 
ensure proper electrocardiographic gating. In those patients 
with an intravenous route available, late gadolinium enhance-
ment study can be considered. 
In summary, an MRI protocol should be tailored accord-
ing to the patient’s age and likelihood of compliance, as well 
as the presence of other findings, instead of using the proto-
col that is used for adults. Importantly, MRI should be per-
formed and interpreted by experienced examiners in these 
cases to reduce the number of false positive and false negative 
readings. 
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